Ambroxol for Parkinson's Disease
Also known as: Mucosolvan
An over-the-counter mucolytic being repurposed as a GBA activator for Parkinson's — targeting the lysosomal dysfunction pathway linked to alpha-synuclein accumulation.
Mechanism of Action
Ambroxol is a pharmacological chaperone that binds glucocerebrosidase (GCase/GBA1) in the ER, stabilizing the enzyme and promoting its trafficking to lysosomes. Enhanced lysosomal GCase activity improves glucosylceramide metabolism and alpha-synuclein clearance. This is particularly relevant for GBA-PD patients but may benefit non-GBA PD through improved lysosomal function.
General mechanism: GBA1/GCase pharmacological chaperone. Enhances lysosomal function and alpha-synuclein clearance.
Current Evidence
The AIM-PD trial showed that high-dose ambroxol crosses the BBB, increases GCase activity in CSF, and reduces alpha-synuclein levels. Well-tolerated in PD patients. Larger efficacy trials are underway. Decades of safety data from mucolytic use.
Clinical Status: Phase II trials for Parkinson's. OTC mucolytic in many countries. Repurposing effort led by academic researchers.
Safety Profile
Excellent safety from decades of OTC use as mucolytic. Well-tolerated at high doses (up to 1.26g/day) in PD trials.
Key Research Questions
- Does ambroxol's GCase activation benefit non-GBA mutation carriers?
- What is the optimal dose for CNS GCase enhancement?
- Can ambroxol slow alpha-synuclein aggregation as measured by SAA biomarker?